88 results
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
6 Nov 19
Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019
9:28am
at ObesityWeek 2019
— Data show treatment effect of setmelanotide on additional secondary endpoints, including body mass index —
— Additional safety … including diastolic blood pressure, systolic blood pressure and heart rate. Additional
analyses of safety data from the Phase 3 trials in POMC
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
8 Mar 19
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
4:04pm
the safety and efficacy of setmelanotide in people with BBS and Alström syndrome.
· In November 2018, Rhythm presented updated clinical data from its … continued to show that treatment with setmelanotide leads to a reduction in body weight and decreased appetite. Safety data in individuals with Alström
8-K
EX-99.2
RYTM
Rhythm Pharmaceuticals Inc.
28 Mar 19
Rhythm Pharmaceuticals Announces Promising Clinical Data in MC4R Pathway Heterozygous Obesity and Strategy for Further Development
4:00pm
% 5 7 150 (330) 4.6 (10.1) 3.0% NA NA
Safety profile for all 13 HET patients: Setmelanotide continues to be well-tolerated No serious adverse events … (AEs) reported No new discontinuations due to AEs since those reported in June 2018 Overall safety profile remains consistent with previous updates
10-K
x80bu213d
12 Mar 18
Annual report
12:00am
DRS
1ksakv62jsks jl
11 Jun 18
Draft registration statement
12:00am
8-K
EX-99.1
4eli4yock9h2 cbue68w
8 Jan 19
Regulation FD Disclosure
12:00am
424B4
czyrncm
21 Jun 18
Prospectus supplement with pricing info
4:55pm
8-K
6lzc3md usdtu
6 Dec 23
Other Events
4:30pm